Company Marizyme, Inc.

Equities

GBSX

US5703721028

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Delayed OTC Markets Other stock markets 11:31:18 2024-05-07 EDT			5-day change	1st Jan Change
0.055 ^USD	+3.77%		+3.77%	-45.05%

02-06	Marizyme, Inc. Announces Resignation of Julie Kampf from the Board of Directors	CI
2023	Marizyme, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Marizyme, Inc. is a multi-technology life science company. The Company is engaged in the development and commercialization of medical technologies that improves patient health outcomes. Its products include DuraGraft, MATLOC 1 and Krillase. DuraGraft is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery. MATLOC is a lab-on-chip digital screening and diagnostic device platform, which is being developed for quantitative chronic kidney disease (CKD) assessment. Krillase can be used in the treatment of chronic wounds and burns, and other clinical applications. Its DuraGraft is an endothelial damage inhibitor (EDI), indicated for cardiac bypass, peripheral bypass, and other vascular surgeries.

Number of employees: 13

USD in Million	2021	Weight	2022	Weight	Delta
Life Science Technologies 100.0 %	0	100.0 %	0	100.0 %	+11.04%

USD in Million	2021	Weight	2022	Weight	Delta
United States 100.0 %	0	100.0 %	0	100.0 %	+11.04%

Managers	Title	Age	Since
David Barthel CEO	Chief Executive Officer	67	21-11-15
George Kovalyov DFI	Director of Finance/CFO	39	21-12-20
Vithalbhai Dhaduk CHM	Chairman	71	21-02-21
Donald Very CTO	Chief Tech/Sci/R&D Officer	66	20-12-01
Catherine Pachuk CTO	Chief Tech/Sci/R&D Officer	68	20-06-30
Harrison Ross IRO	Public Communications Contact	33	21-12-22
Amar Dhaduk PRN	Corporate Officer/Principal	-	20-12-31

Members of the board	Title	Age	Since
David Barthel CEO	Chief Executive Officer	67	21-11-15
Vithalbhai Dhaduk CHM	Chairman	71	21-02-21
Terry Brostowin BRD	Director/Board Member	65	18-12-13
Nilesh Patel BRD	Director/Board Member	59	22-04-21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	46,666,760	31,587,419 ( 67.69 %)	0	67.69 %

Name	Equities	%	Valuation
Vithalbhai Dhaduk 9.880 %	4,610,548	9.880 %	336 570 $
Bologna Family Restaurant SpA 8.698 %	4,058,897	8.698 %	296 299 $
Conley Emmanuelle Schleipfer 5.476 %	2,555,640	5.476 %	186 562 $
Amar Dhaduk 4.916 %	2,294,097	4.916 %	167 469 $
Payal Dhaduk 4.916 %	2,294,097	4.916 %	167 469 $
Darpan Dhaduk 4.916 %	2,294,097	4.916 %	167 469 $
Oleg Kovalyov 2.885 %	1,346,410	2.885 %	98 288 $
BWL Investments Ltd. 1.388 %	647,759	1.388 %	47 286 $
George Kovalyov 1.132 %	528,052	1.132 %	38 548 $
Harrison Ross 0.9543 %	445,344	0.9543 %	32 510 $

Marizyme, Inc.

555 Heritage Drive Suite 205

33458, Jupiter

http://www.marizyme.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
MARIZYME, INC.	-45.05%	2.57M
VERTEX PHARMACEUTICALS INCORPORATED	+4.76%	111B
REGENERON PHARMACEUTICALS, INC.	+11.98%	105B
BIONTECH SE	-12.76%	22.34B
ARGENX SE	-3.70%	21.93B
GENMAB A/S	-6.03%	18.59B
WUXI APPTEC CO., LTD.	-35.21%	18.12B
BEIGENE, LTD.	-10.59%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+4.12%	13.7B
SAREPTA THERAPEUTICS, INC.	+37.27%	12.45B

Bio Therapeutic Drugs